In a regulatory filing on Wednesday night, it was disclosed that on November 25, Roivant Sciences and Millennium Pharmaceuticals entered into a stock purchase agreement pursuant to which Roivant agreed to purchase an aggregate of 3,500,000 common shares of Myovant Sciences from Millennium at a price of $15.00 per common share, which equates to an aggregate purchase price of $52.5M. The stock purchase agreement provides that these common shares will be delivered to Roivant within 10 calendar days following execution of the agreement, or a later date as mutually agreed by the parties.